Teva Backs Off From Big Acquisitions In 2012, But Isn't Done Spending Just Yet
This article was originally published in PharmAsia News
Teva brought in Cephalon and a vastly expanded Japanese operation in 2011, and now the company expects to carve out local deals in new markets, execs tell investors during the annual JP Morgan Healthcare Conference.
You may also be interested in...
Most of the top 20 generic drug makers are subsidiaries of diversified pharmas or smaller generics-only plays based in the Far East. But diversification, although long a goal, is now urgent for the three major independent generic firms – Teva, Mylan and Watson.
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.